Atherosclerosis plus最新文献

{"title":"Safety and efficacy of edoxaban monotherapy after bioabsorbable polymer everolimus-eluting stent implantation in a human-like coronary atherosclerotic porcine model","authors":"Daisuke Kitano ,&nbsp;Suguru Migita ,&nbsp;Yuxin Li ,&nbsp;Yutaka Koyama ,&nbsp;Katsunori Fukumoto ,&nbsp;Sayaka Shimodai-Yamada ,&nbsp;Akira Onishi ,&nbsp;Daiichiro Fuchimoto ,&nbsp;Shunichi Suzuki ,&nbsp;Yoshiyuki Nakamura ,&nbsp;Atsushi Hirayama ,&nbsp;Hiroyuki Hao ,&nbsp;Yasuo Okumura","doi":"10.1016/j.athplu.2025.01.002","DOIUrl":"10.1016/j.athplu.2025.01.002","url":null,"abstract":"<div><h3>Background</h3><div>The combination of antiplatelet and antithrombotic drugs increases the risk of bleeding in patients with atrial fibrillation after coronary drug-eluting stent (DES) implantation. However, the appropriateness of direct-acting oral anticoagulant (DOAC) monotherapy at the time of stent implantation remains uncertain. The objective of this study was to evaluate the safety and efficacy of DOAC monotherapy, specifically using factor Xa inhibitors such as edoxaban, in a low-density lipoprotein receptor knockout (LDL-R^−/−) miniature pig model of human-like unstable coronary plaques compared to conventional dual-antiplatelet therapy (DAPT).</div></div><div><h3>Methods</h3><div>We evaluated the safety and efficacy of edoxaban monotherapy in the LDL-R^−/− pig model with human-like unstable coronary plaques induced by a high-cholesterol, high-fat diet. Animals underwent DES implantation, followed by four weeks of treatment with either edoxaban monotherapy (3 mg/kg/day) or the DAPT regimen (aspirin 100 mg/day and clopidogrel 75 mg/day). Outcomes were assessed by optical coherence tomography (OCT), virtual histology intravascular ultrasound (iMap-IVUS), and histology. Key endpoints included in-stent thrombus formation, neointimal thickness, and coronary plaque composition.</div></div><div><h3>Results</h3><div>Edoxaban monotherapy demonstrated a significantly thinner neointimal layer (120.0 [92.5–160.0] μm vs. 210.0 [180.0–240.0] μm, <em>p</em> &lt; 0.001) and smaller neointimal area (1.06 [0.82–1.46] mm² vs. 1.84 [1.61–2.24] mm², <em>p</em> &lt; 0.001) compared to DAPT. Neointimal coverage, fibrin deposition, and inflammatory cell infiltration were comparable between groups. No in-stent thrombi were observed in either group. iMap-IVUS findings indicated that edoxaban monotherapy significantly suppressed the increase in lipidic and necrotic plaque area while promoting fibrotic area expansion.</div></div><div><h3>Conclusions</h3><div>Edoxaban monotherapy demonstrated superior efficacy in suppressing neointimal hyperplasia and stabilizing coronary plaques compared to DAPT with equivalent safety in preventing in-stent thrombus formation. These results provide important preclinical evidence supporting the potential of DOAC monotherapy as an antithrombotic strategy after DES implantation and warrant further investigation in clinical trials.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 59-67"},"PeriodicalIF":1.4,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143263756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Inclisiran: Early LDL-C target achievement in a real-life population”","authors":"Francesco Briani ,&nbsp;Mauro Bagli ,&nbsp;Gabriele Venturi ,&nbsp;Francesco Bacchion ,&nbsp;Antonio Mugnolo","doi":"10.1016/j.athplu.2025.01.001","DOIUrl":"10.1016/j.athplu.2025.01.001","url":null,"abstract":"<div><h3>Background and objectives</h3><div>Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with atherosclerotic cardiovascular diseases. Inclisiran, a small interfering RNA, has been observed to effectively and sustainably reduce LDL-C in large randomized controlled trials (RCTs); however, real-world data on its short-term efficacy and use are limited. This study aims to assess the efficacy and safety of inclisiran in a real-life population within one month from the first administration.</div></div><div><h3>Methods</h3><div>This observational, single-center, retrospective cohort study included patients affected by dyslipidemia who could not achieve their LDL-C target despite a maximum tolerated oral lipid-lowering therapy (LLT). 284 mg Inclisiran was subcutaneously administered. Blood samples were collected before the inclisiran administration and at week and one month afterward with the aim toevaluate achievement of LDL-C targets at these time intervals (primary endpoint) and reduction in LDL-C levels (secondary endpoint).</div></div><div><h3>Results</h3><div>From September 2022 to December 2023, inclisiran was administered to 33 patients at Mater Salutis Hospital. After exclusion of two patients due to statin therapy modification or discontinuation during follow-up, a final number of 31 patients were included. At a median follow-up of 32 (IQ_1-3 30–37) days, 21 (67.7 %) patients reached their LDL-C target (primary endpoint). At 7 days, LDL-C mean value decreased from 123.6 ± 42.1 mg/dl to 97.9 ± 53.6 mg/dl, (p &lt; 0.001), with a 29.9 ± 20.6 % reduction. At 32 days, LDL-C mean value declined to 58.5 ± 42.8 mg/dl (p &lt; 0.001), with a 56.9 ± 20.9 % reduction.</div></div><div><h3>Conclusion</h3><div>In a real-life single center population, inclisiran safely led to LDL-C target achievement within one month. Significantly reduction of LDL-C levels were already present in the early days after the first administration.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 54-58"},"PeriodicalIF":1.4,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143263754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-atherosclerotic effects of natural compounds targeting lipid metabolism and inflammation: Focus on PPARs, LXRs, and PCSK9","authors":"Marcella Palumbo ,&nbsp;Martina Ugolotti ,&nbsp;Francesca Zimetti ,&nbsp;Maria Pia Adorni","doi":"10.1016/j.athplu.2024.12.004","DOIUrl":"10.1016/j.athplu.2024.12.004","url":null,"abstract":"<div><div>A large body of evidence has shown that modulation of the nuclear receptors peroxisome proliferator-activated receptors (PPARs), the liver X receptors (LXRs), the proprotein convertase subtilisin/kexin type 9 (PCSK9) and inflammatory processes by natural compounds has hypolipidemic and anti-atherosclerotic effects. These beneficial outcomes are certainly related to the crucial function of these targets in maintaining cholesterol homeostasis and regulating systemic inflammation. Currently, the therapeutic scenario for cardiovascular diseases (CVD) offers a plethora of widely validated and functional pharmacological treatments to improve the health status of patients. However, patients are increasingly sceptical of pharmacological treatments which are often associated with moderate to severe side effects. The aim of our review is to provide a collection of the most recent scientific evidence on the most common phytochemicals, used for centuries in the Mediterranean diet and traditional chinese medicine that act on these key regulators of cholesterol homeostasis and systemic inflammation, which could constitute important tools for CVD management.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 39-53"},"PeriodicalIF":1.4,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of NAFLD-related SNPs on the carotid atherosclerosis development; a five-year prospective observational study","authors":"Hiroaki Ikezaki ,&nbsp;Ryoko Nakashima ,&nbsp;Yuji Matsumoto ,&nbsp;Azusa Ohta ,&nbsp;Sho Yamasaki ,&nbsp;Satoshi Hiramine ,&nbsp;Koji Takayama ,&nbsp;Eiichi Ogawa ,&nbsp;Masayuki Murata ,&nbsp;Norihiro Furusyo ,&nbsp;Jun Hayashi ,&nbsp;Nobuyuki Shimono ,&nbsp;Ernst J. Schaefer","doi":"10.1016/j.athplu.2024.12.003","DOIUrl":"10.1016/j.athplu.2024.12.003","url":null,"abstract":"<div><h3>Background and aims</h3><div>The prevalence of metabolic dysfunction associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a significant public health concern with an increased atherosclerotic cardiovascular disease risk. This study investigates the impact of NAFLD-related single nucleotide polymorphisms (SNPs) on carotid atherosclerosis development in a Japanese population without diabetes, dyslipidemia, and hypertension.</div></div><div><h3>Methods</h3><div>The prospective observational study, part of the Kyushu and Okinawa Population Study (KOPS), included 945 participants (median age 55 [47, 63]) without carotid atherosclerosis, increased alcohol intake, diabetes, dyslipidemia, hypertension, or chronic hepatitis at baseline. NAFLD-related SNPs (<em>GCKR</em>, <em>NCAN</em>, <em>and PNPLA3</em>) were genotyped, and carotid intima-media thickness (cIMT) was measured using ultrasonography. Univariate and multivariate regression analyses were performed to assess the association of NAFLD-related SNPs on newly developed carotid atherosclerosis over five years.</div></div><div><h3>Results</h3><div>After five years, 125 (13.2 %) participants developed carotid atherosclerosis. The <em>NCAN</em> (rs2228603) T allele was associated with a lower incidence rate of carotid atherosclerosis (4.7 % in <em>NCAN</em> CT/TT genotype vs. 13.9 % in CC genotype; p = 0.04), and <em>NCAN</em> T allele carriers exhibited a favorable lipid profile. These associations were not altered by either recruiting area or obese. The <em>GCKR</em> T allele and <em>PNPLA3</em> C allele were associated with low carotid atherosclerosis development rates but were not significant.</div></div><div><h3>Conclusions</h3><div>Our results suggested that some NAFLD-related SNPs may influence atherosclerosis through lipid metabolism among Japanese individuals without metabolic syndrome.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 10-17"},"PeriodicalIF":1.4,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11719292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HDL-associated vitamin D binding protein levels are inversely associated with necrotic plaque burden in psoriasis","authors":"M.P. Playford ,&nbsp;H. Li ,&nbsp;A.K. Dey ,&nbsp;E.M. Florida ,&nbsp;H.L. Teague ,&nbsp;S.M. Gordon ,&nbsp;N.N. Mehta","doi":"10.1016/j.athplu.2024.12.002","DOIUrl":"10.1016/j.athplu.2024.12.002","url":null,"abstract":"<div><h3>Background and aims</h3><div>Vitamin D binding protein (DBP) serves a dual function as a vitamin D carrier and actin scavenger. Free DBP is present in high concentrations in serum, while a smaller pool is bound to lipoproteins like HDL and VLDL. The role of DBP's interaction with lipoproteins remains unclear. Given that HDL has been proposed to have both atheroprotective and anti-inflammatory properties, we sought to compare whether HDL-associated DBP and/or total serum DBP could serve as useful biomarkers for assessing disease severity in psoriasis and cardiovascular disease.</div></div><div><h3>Methods</h3><div>Psoriasis (PSO) patients (N = 83), which were part of a prospective, observational cohort and non-psoriasis (non-PSO) subjects (n = 35) underwent blood collection for HDL purification by liquid chromatography and CCTA scans to assess coronary plaque burden. Serum and HDL-bound DBP levels were measured by ELISA.</div></div><div><h3>Results</h3><div>The psoriasis cohort was middle-aged (mean ± IQR: 50 (38–59), predominantly male (n = 55, 66 %) and had moderate-to-severe skin disease [psoriasis area severity index score, PASI score, med (IQR): 9.6 (6–18.3)]. Consistent with our previous reports, PSO patients had significantly higher Framingham Risk Score (FRS), high sensitivity C-reactive protein (hs-CRP), Body Mass Index (BMI), insulin resistance (HOMA-IR) and total coronary plaque burden, driven by the rupture-prone non-calcified necrotic core. However, while the concentration of serum DBP (S-DBP) between PSO and non-PSO was unchanged (PSO: 177.80 (125.77–250.99) vs non-PSO: 177.74 (104.32–254.04), the concentration of DBP associated with HDL (HDL-DBP) was decreased in psoriatics (PSO μg/ml: 1.38 (0.64–2.75) vs non-PSO: 1.72 (1.18–3.90). Although both S-DBP and HDL-DBP levels showed inverse correlations with a measure of skin disease severity (PASI) (S-DBP, Rho = −0.022 vs HDL-DBP, Rho = −113), only HDL-DBP exhibited an inverse relationship with necrotic plaque burden [Rho −0.226, p = 0.085 vs S-DBP (0.041, p = 0.76)]. This relationship was strengthened after adjusting for traditional cardiovascular risk factors such as age and sex (β = −0.237, p = 0.045), FRS (β = −0.295, p = 0.033) and including biological treatment and HDL-cholesterol (β = −0.213, p = 0.048).</div></div><div><h3>Conclusions</h3><div>In conclusion, we found HDL-DBP levels may better capture the severity of psoriatic disease and association with cardiovascular risk factors than S-DBP.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 32-38"},"PeriodicalIF":1.4,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in patterns and outcomes of dyslipidemic patients with acute coronary syndrome: A tertiary cardiac center registry","authors":"Hesham Taha ,&nbsp;Mohammad Alshehri ,&nbsp;Hossam El-Hosary ,&nbsp;Abdalla Elagha ,&nbsp;Hosam Mahrous ,&nbsp;Mirna Shaker ,&nbsp;Omar Younis ,&nbsp;Mohamed Saad","doi":"10.1016/j.athplu.2024.11.004","DOIUrl":"10.1016/j.athplu.2024.11.004","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 18-24"},"PeriodicalIF":1.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging oral therapeutic strategies for inhibiting PCSK9","authors":"Nicola Ferri ,&nbsp;Giorgia Marodin","doi":"10.1016/j.athplu.2024.11.003","DOIUrl":"10.1016/j.athplu.2024.11.003","url":null,"abstract":"<div><div>Pharmacological inhibition of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) have been firmly established to be an effective approach to reduce low-density lipoprotein (LDL) cholesterol levels and cardiovascular events. Subcutaneous administration of monoclonal antibodies (evolocumab and alirocumab) every 2 or 4 weeks determined a 60 % reduction of LDL cholesterol levels, while the GalNac-siRNA anti PCSK9 (inclisiran) provided an effective lipid lowering activity (−50 %) after an initial subcutaneous dose, repeated after 3 months and followed by a maintenance dose every 6 months. Although these two approaches have the potentiality to bring the majority of patients at high and very-high cardiovascular risk to the appropriate LDL cholesterol targets, their cost and subcutaneous administration represent a strong limitation for their large-scale use. These problems could be overcome by the development of small chemical molecules anti PCSK9 as oral therapy for controlling hypercholesterolemia. In the present review, we summarized the pharmacological properties of oral anti PCSK9 molecules that are currently under clinical development (DC371739, CVI-LM001, and AZD0780), including the mimetic peptides enlicitide decanoate (MK-0616) and NNC0385-0434.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 25-31"},"PeriodicalIF":1.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Familial hypercholesterolemia – Targeted whole gene sequencing as a diagnostic approach","authors":"Emma Adolfsson ,&nbsp;Nils Johan Fredriksson ,&nbsp;Jon Jonasson ,&nbsp;Anna Nordenskjöld ,&nbsp;Anna Green","doi":"10.1016/j.athplu.2024.12.001","DOIUrl":"10.1016/j.athplu.2024.12.001","url":null,"abstract":"<div><h3>Background and aims</h3><div>Familial hypercholesterolemia (FH) and other disorders with similar features are common genetic disorders that remain underdiagnosed and undertreated, due in part to the cost of screening. The aim of this study was to design and implement a whole gene targeted NGS panel for the molecular diagnosis of FH and statin intolerance with an emphasis on high quality variant calling, including copy number analysis.</div></div><div><h3>Methods</h3><div>A whole gene panel for hybridisation-based short read NGS was designed for the dominant FH-genes low density lipoprotein receptor (<em>LDLR</em>), apolipoprotein B (APOB), proproteinconvertas subtilisin/kexin type 9 (PCSK9), apolipoprotein E (APOE) and the recessive FH-genes low density lipoprotein receptor adaptor protein 1 (<em>LDLRAP1</em>), ATP binding cassette subfamily member 5/8 (ABCG5/8) and lipase A, lysosomal acid type (<em>LIPA</em>), as well as solute carrier organic anion transporter family member 1B1 (<em>SLCO1B1</em>), not an FH gene but linked to statin intolerance. Polygenetic risk score markers were also included. The panel was used for screening of a Swedish FH-study population (n = 133).</div></div><div><h3>Results</h3><div>The panel sequencing resulted in high coverage and confident variant calling of included genes. Known causal variants were found in common dominant FH-genes in 43 % of the cohort. Copy number variants were found in <em>LDLR</em> in 10 individuals and a whole gene deletion of <em>SLCO1B1</em> in one individual. In addition, coding variants in recessive genes and rare non-coding intronic and untranslated region variants were found in a large proportion of the study individuals highlighting the need for extended gene panels.</div></div><div><h3>Conclusions</h3><div>This new tool can be used for a comprehensive high-quality molecular genetic analysis according to guidelines for the diagnosis and treatment of FH.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"59 ","pages":"Pages 1-9"},"PeriodicalIF":1.4,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11719334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A cross-tissue transcriptome-wide association study identifies WDPCP as a potential susceptibility gene for coronary atherosclerosis","authors":"Xinyue Hu ,&nbsp;Guanglei Chen ,&nbsp;Xiaofang Yang ,&nbsp;Jin Cui ,&nbsp;Ning Zhang","doi":"10.1016/j.athplu.2024.11.002","DOIUrl":"10.1016/j.athplu.2024.11.002","url":null,"abstract":"<div><h3>Background</h3><div>Coronary atherosclerosis (CAS) is a complex chronic inflammatory disease with significant genetic and environmental contributions. While genome-wide association studies (GWAS) have pinpointed many risk loci, over 75 % are in non-coding regions, complicating functional analysis and understanding gene-disease mechanisms.</div></div><div><h3>Methods</h3><div>We conducted a cross-tissue transcriptome-wide association study (TWAS) using data from the GWAS Catalog (16,041 cases, 440,307 controls) and the Genotype-Tissue Expression (GTEx) v8 eQTL dataset. Initially, we used the Unified Test for Molecular Signatures (UTMOST) for analysis, followed by validation with Functional Summary-based Imputation (FUSION) and conditional and joint (COJO) analyses. Candidate genes were further refined using Multi-marker Analysis of Genomic Annotation (MAGMA). Causal relationships were assessed through Summary Data-Based Mendelian Randomization (SMR), colocalization analysis (COLOC), and Mendelian Randomization (MR). GeneMANIA was used to identify interacting genes, and Phenome-Wide Association Study (PheWAS) was employed to enhance the results.</div></div><div><h3>Results</h3><div>UTMOST identified 33 susceptibility genes for CAS. Out of these, 17 met stringent criteria in both UTMOST and FUSION analyses. Combining results from UTMOST, FUSION, and MAGMA, we identified four critical candidate genes. WDPCP was the only gene to pass SMR, COLOC, and MR analyses, confirming its causal role in CAS. GeneMANIA revealed additional interacting genes, and PheWAS validated WDPCP's role as a susceptibility gene.</div></div><div><h3>Conclusion</h3><div>WDPCP is a potential novel susceptibility gene for CAS, influencing endothelial function, lipid metabolism, and coronary artery development. This study extends GWAS findings, highlighting WDPCP's potential as a therapeutic target and its consistent expression across different tissues. Further validation studies are warranted.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"58 ","pages":"Pages 59-74"},"PeriodicalIF":1.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142742945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world data lipid profiles in one million colombian adults: The LiPAC million person study","authors":"Claudia C. Colmenares-Mejía ,&nbsp;Marcela Godoy-Corredor ,&nbsp;Esteban Morales-Mendoza ,&nbsp;Diego Alejandro Pinto-Pinzón ,&nbsp;José Medardo Rozo-Vanstrahlen ,&nbsp;Jairo Acuña-Olmos ,&nbsp;Liliana Hilarión-Gaitán ,&nbsp;María del Pilar Suarez-Ramos ,&nbsp;Diego Alberto Ruiz-Amaya ,&nbsp;Fredy Rolando Salazar-Heredia ,&nbsp;Johana Vargas-Rodríguez ,&nbsp;Mario A. Isaza-Ruget","doi":"10.1016/j.athplu.2024.11.001","DOIUrl":"10.1016/j.athplu.2024.11.001","url":null,"abstract":"<div><h3>Background and aims</h3><div>Lipid profile results are of clinical interest for assessing the presence of dyslipidemia and the risk of cardiovascular disease. This study aimed to characterize lipid profile parameters in a large adult population from different regions of Colombia.</div></div><div><h3>Methods</h3><div>Cross-sectional study. Adults with a complete lipid profile [TC, c-HDL, non-c-HDL, c-LDL, Triglycerides] from a national reference laboratory between 2018 and 2022 were included. Lipid profile levels are reported as medians and adjusted means and are also presented according to different guideline thresholds. Mixed dyslipidemia frequencies are also reported.</div></div><div><h3>Results</h3><div>1,030,195 subjects were included, with a median age of 49 years (IQR 36–61 years); 59.8 % were females. Adjusted mean value for TC was 188.1 mg/dl (CI95 % 188.0–188.2), 110.1 mg/dl (CI95 % 110.0–110.1) for c-LDL, 45.9 mg/dl (CI95 % 45.9–46.0) for c-HDL, 139.1 mg/dl (CI95 % 139.0–139.2) for non-c-HDL and 129.5 mg/dl (CI95 % 129.4–129.6) for triglycerides. The most frequent single dyslipidemia was c-HDL &lt;40 mg/dL (n = 86,725, 8.4 %), and the most common mixed dyslipidemia was TC ≥ 200 mg/dL + c-LDL &gt;130 mg/dL (n = 138,366, 17.0 %). Elevated c-LDL (≥130 mg/dL) was found in 32.4 % of the population, while c-LDL levels ≥190 mg/dL were observed in 2.0 % (n = 21,045). Triglyceride levels ≥500 mg/dL were identified in 0.3 % (n = 3103).</div></div><div><h3>Conclusion</h3><div>This large study on lipid markers from a selected sample of Colombian adults’ highlights variations in dyslipidemia by gender, age, and region. The findings emphasize the need for targeted interventions to reduce cardiovascular risk. Identifying high-risk groups is essential to improving outcomes in developing countries.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"58 ","pages":"Pages 51-58"},"PeriodicalIF":1.4,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142703592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}